Journal
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
Volume 11, Issue 7, Pages 593-599Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/187152011796817727
Keywords
Angiogenesis; Chemoresistance; Focal Adhesion Kinase; Metastasis; Migration of tumor cells; Small molecule inhibitors
Categories
Funding
- Novartis
- Pfizer
- Roggenbuck Foundation, Hamburg, Germany
Ask authors/readers for more resources
Since its first description Focal Adhesion Kinase (FAK), a cytoplasmatic tyrosine kinase, has been implicated in the formation and progression of solid and liquid malignant tumors. Therefore orally available selective small molecule inhibitors of FAK have been developed, three of them (PF-562-271, PF-04554878 and GSK2256098) are already in clinical testing. This review discusses the recent data obtained from these Phase 1 trials. We also discuss available data on the mechanisms of action of these inhibitors in carcinogenesis and demonstrate that FAK plays an important role in neoangiogenesis which is a crucial step in cancer growth.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available